

March 1, 2023

---

# CymaBay Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference

NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 33rd Annual Healthcare Conference.

## ***Oppenheimer 33rd Annual Healthcare Conference***

Date: Monday, March 13  
Time: 11:20 am Eastern Time  
Format: Fireside Chat  
Webcast: <http://ir.cymabay.com/events>

## **About CymaBay**

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical need through a pipeline of innovative therapies. Our deep understanding of the underlying mechanisms of liver inflammation and fibrosis, and the unique targets that play a role in their progression, have helped us receive breakthrough therapy designation (U.S. Food and Drug Administration), PRiority MEdicines status (European Medicines Agency) and orphan drug status (U.S. and Europe) for seladelpar, a first-in-class treatment for people with primary biliary cholangitis (PBC). Our evidence-based decision-making and commitment to the highest quality standards reflect our relentless dedication to the people, families and communities we serve. To learn more, visit [www.cymabay.com](http://www.cymabay.com) and follow us on [Twitter](#) and [LinkedIn](#).

## **Cautionary Statements**

Any statements made in this press release and at the conference referenced above regarding the potential for seladelpar to treat PBC and potentially improve clinical symptoms of the disease, the potential benefits to patients, and the timing of the release of seladelpar clinical data are forward-looking statements that are subject to risks and uncertainties. Actual outcomes and results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of product development activities; effects observed in trials to date that may not be repeated in the future; any delays or inability to obtain or maintain regulatory approval of product candidates; and the ability to obtain sufficient financing to complete development, regulatory approval and commercialization of product candidates. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by

law.

For additional information about CymaBay visit [www.cymabay.com](http://www.cymabay.com).

**Public Relations Contact:**

Glenn Silver  
Lazar-FINN Partners  
(973) 818-8198  
[Glenn.silver@finnpartners.com](mailto:Glenn.silver@finnpartners.com)

**Investor Relations Contact:**

Hans Vitzthum  
LifeSci Advisors, LLC  
(617) 430-7578  
[Hans@LifeSciAdvisors.com](mailto:Hans@LifeSciAdvisors.com)



Source: CymaBay Therapeutics, Inc.